Chromatin binding by the androgen receptor in prostate cancer

Harri Itkonen, Ian G Mills

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Alterations in transcriptional programs are fundamental to the development of cancers. The androgen receptor is central to the normal development of the prostate gland and to the development of prostate cancer. To a large extent this is believed to be due to the control of gene expression through the interaction of the androgen receptor with chromatin and subsequently with coregulators and the transcriptional machinery. Unbiased genome-wide studies have recently uncovered the recruitment sites that are gene-distal and intragenic rather than associated with proximal promoter regions. Whilst expression profiles from AR-positive primary prostate tumours and cell lines can directly relate to the AR cistrome in prostate cancer cells, this distribution raises significant challenges in making direct mechanistic connections. Furthermore, extrapolating from datasets assembled in one model to other model systems or clinical samples poses challenges if we are to use the AR-directed transcriptome to guide the development of novel biomarkers or treatment decisions. This review will provide an overview of the androgen receptor before addressing the challenges and opportunities created by whole-genome studies of the interplay between the androgen receptor and chromatin.

Original languageEnglish
Pages (from-to)44-51
Number of pages8
JournalMolecular and Cellular Endocrinology
Volume360
Issue number1-2
DOIs
Publication statusPublished - 05 Sep 2012

Bibliographical note

Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Keywords

  • Animals
  • Chromatin
  • Chromatin Immunoprecipitation
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Nucleic Acid Conformation
  • Prostatic Neoplasms
  • Protein Binding
  • Protein Conformation
  • Receptors, Androgen
  • Transcription, Genetic

Fingerprint Dive into the research topics of 'Chromatin binding by the androgen receptor in prostate cancer'. Together they form a unique fingerprint.

  • Cite this